FOSUN HEALTH Logo

Brain Glioma Prevention

catalogue

Brain Glioma Prevention

Brain Glioma Prevention

Brain glioma cannot be prevented, and there is no screening test that would find it in someone without symptoms. Scanning healthy people is not recommended, because glioma is uncommon, no benefit from early detection in this way has been demonstrated, and an incidental finding brings its own consequences. What does exist is defined surveillance for the small groups with an inherited syndrome, and a structured follow-up programme after treatment. In this disease, the useful measures are about recognising symptoms early and about what happens after treatment rather than about preventing the tumour.

Why there is no screening test

Patients reasonably ask why a tumour that can be seen on a scan is not screened for, and the answer is specific:

  • Glioma is uncommon. The great majority of scans performed on people without symptoms would be normal, and the cost and anxiety of scanning a healthy population are substantial.
  • Early detection has not been shown to change the outcome. For a tumour that infiltrates rather than forms a defined mass, finding it before symptoms appear has not been demonstrated to improve what can be achieved by treatment.
  • Incidental findings create their own problems. A scan done without a reason often reveals small abnormalities that are not tumours, leading to further scans, anxiety and sometimes procedures that were never necessary.
  • The exception is a defined syndrome, in which the risk is high enough and defined enough that scheduled surveillance is justified — see below.
  • Symptoms are the effective route to diagnosis. For everyone else, the practical approach is that a first seizure, a progressive deficit or a suspicious headache pattern is assessed promptly rather than observed.

Surveillance in the inherited syndromes

This is the one situation in which imaging is used to detect gliomas before symptoms appear, because the risk is high enough to justify it and a schedule is defined:

  • Neurofibromatosis type 1 — surveillance for optic pathway and other gliomas, usually with imaging during childhood and adolescence, alongside the monitoring the condition requires in any case.
  • Neurofibromatosis type 2 — an established imaging programme covering the brain and spine, which detects ependymoma and other tumours at a stage when treatment is straightforward.
  • Li-Fraumeni syndrome — a coordinated surveillance programme across several tumour types, including periodic brain imaging, carried out under specialist supervision.
  • Lynch syndrome and constitutional mismatch repair deficiency — surveillance for the associated tumours, with brain imaging included where the risk warrants it, particularly in childhood for the latter.
  • Tuberous sclerosis complex — imaging surveillance for the associated brain tumours, for which targeted treatment is also available when needed.
  • What to do if you have one of these diagnoses — follow the surveillance that has been set out for your condition, and tell any new clinician about it, because the schedule is specific rather than general.

The exposures that can be limited

The avoidable share of the risk is small, and it is worth being straightforward about what it consists of rather than offering measures with no evidence:

  • Radiation exposure is cumulative and partly controllable. No necessary imaging should be avoided, but unnecessary CT examinations should not be requested. This is a reasonable principle rather than a claim that diagnostic imaging causes glioma, which it has not been shown to do.
  • Radiotherapy decisions already take this into account. Where radiotherapy to the head is needed, particularly in childhood, the dose and the volume treated are planned to limit exposure of normal tissue — which is also why the plan is shaped so carefully rather than simply covering a region.
  • Addressing smoking is still worthwhile, not because it causes glioma but because it causes other cancers and increases the risks of surgery and of clot formation.
  • Nothing else has an evidence base. No diet, supplement or protective device has been shown to reduce the risk of glioma, and the ones marketed for that purpose should be treated with caution.

Symptoms that should be assessed

Because there is no screening test, the practical substitute is knowing which symptoms warrant assessment rather than waiting. These are the ones that should prompt a medical opinion promptly:

  • A first seizure at any age — always warrants imaging, because in someone with no history of epilepsy a structural cause has to be excluded or found.
  • A progressive neurological deficit — weakness on one side, difficulty finding words, or loss of part of the visual field, especially developing over days to weeks rather than suddenly.
  • A headache that is different in character — worst on waking, worse on bending or coughing, progressive over weeks, or waking the patient from sleep.
  • A headache with vomiting, drowsiness or visual change — features of raised pressure rather than of ordinary headache, and a reason for urgent assessment rather than a routine appointment.
  • A change in personality, memory or judgement noticed by family — easily attributed to stress or age, and worth investigating when it appears alongside any of the above.
  • A known syndrome with new symptoms — for anyone under surveillance, a new symptom should be reported rather than fitted into the next scheduled scan.

What prevention cannot do

An honest account of the limits is more useful than optimism, and in this disease the limits are specific:

  • It cannot prevent the disease. No intervention has been shown to reduce the chance of developing a glioma, which is why attention is directed at recognising symptoms and at treating the tumour well.
  • It cannot replace treatment once the tumour is present — no dietary or lifestyle measure substitutes for surgery, radiotherapy or chemotherapy, and delaying treatment in favour of such measures has a cost.
  • It cannot prevent recurrence in the diffuse gliomas. Removal and treatment reduce the amount of tumour and delay growth, but the infiltrating nature of the disease means recurrence is expected rather than exceptional.
  • It cannot restore function that tissue loss has removed — rehabilitation can recover a great deal, particularly when started early, but improvement depends on what was lost and why.
  • And a normal scan does not provide permanent certainty — if symptoms are persistent or progressive, they should be assessed even if recent imaging was reassuring.

What follow-up looks like

Follow-up after treatment for a glioma has a defined structure, and knowing it makes the process manageable:

  • MRI at defined intervals — more frequent in the first period after treatment and then widening, with the specific schedule stated in writing rather than left to be inferred.
  • Distinguishing progression from treatment effect — a change on the scan soon after radiotherapy may be treatment effect rather than tumour growth, and perfusion imaging, spectroscopy or a repeat scan at a short interval is used to judge which it is before any decision is made.
  • Seizure control — reviewed at each visit, aiming to keep seizures controlled while reducing medication where that is safe. Driving and safety advice follows from this and is worth asking about directly.
  • Rehabilitation continues after treatment ends, because functional recovery extends well beyond the period of hospital care, and because gains are greatest when therapy is sustained.
  • Steroid doses are reviewed rather than continued — the aim is the lowest dose and the shortest period that works, and a plan for reducing them should be explicit.
  • What to report between scans — new or worsening seizures, a new focal deficit, headache that is increasing or waking the patient, drowsiness, or fever while on steroids.

Frequently Asked Questions

Should I be scanned because a relative had a glioma?

No. A glioma in one relative increases your risk only modestly, and no imaging-based surveillance is recommended for relatives of an ordinary patient, because the risk is small and no benefit from early detection in this way has been demonstrated. The exception is a family with a recognisable inherited syndrome — several different tumour types across generations, cancers at unusually young ages, or features of one of the conditions described on this page — where genetic assessment is appropriate and a surveillance programme is defined.

Can anything reduce the chance of the tumour coming back?

There is no diet, supplement or lifestyle measure that has been shown to reduce recurrence. What does influence what happens is the treatment itself, which is why completeness of removal matters, why radiotherapy is given to the surrounding tissue, why the molecular type determines which drug is used, and why follow-up imaging is scheduled to detect a change early rather than waiting for symptoms. Adherence to the plan — including taking oral chemotherapy as prescribed and attending monitoring — is the concrete factor within a patient's control.

How often will I need scans after treatment?

The schedule is set individually, generally with more frequent imaging in the period shortly after radiotherapy and then widening intervals as time passes, and it differs by tumour type and grade. The important practical point is that the schedule, with dates, should be given to you in writing, together with a statement of what would cause an earlier scan — a new symptom, a seizure, or a change reported by you rather than detected by the calendar. If you are being followed in more than one place, ask who holds the schedule.

What should I do if I have a seizure again?

Report it, and report it promptly, rather than treating it as a setback to be managed privately. A seizure may indicate that the tumour has changed, that the medication dose needs adjusting, or that something else is happening, and the decision about which requires a clinical assessment. If a seizure lasts more than a few minutes or does not stop, it is a medical emergency and requires immediate treatment. Practical matters — driving, swimming, working at height — follow from seizure control and local rules, and are worth discussing explicitly rather than deciding alone.

Ask what your follow-up interval should be

Send the pathology and molecular report, the operative report, the radiotherapy plan if given, the most recent MRI report with dates, and the current anti-epileptic and steroid medication. Our neuro-oncology team will return a written assessment within 48 hours of the file being complete, including the follow-up interval appropriate to your tumour type.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*